How Bank of America (Merrill Lynch) Currently Rates Intersect ENT (NASDAQ:XENT)
Bank of America (Merrill Lynch) issued “Buy” rating on Intersect ENT (NASDAQ:XENT). The firm began issuing coverage on shares of XENT in recent note issued to clients on Friday morning.
From a total of 6 analysts covering Intersect ENT (NASDAQ:XENT) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $29 while the lowest target price is $22. The mean of all analyst targets is $25.67 with a 40.28% above today’s ($21.15) stock price. Intersect ENT was the topic of 4 analyst reports since August 17, 2015 according to the firm StockzIntelligence Inc. Canaccord Genuity maintained shares on October 1 with “Buy” rating.
The stock increased 7.91% or $1.55 during the last trading session, striking $21.15. Approximately 1.36 million shares of stock traded hands or 192.77% up from the average. Intersect ENT Inc (NASDAQ:XENT) has declined 18.09% since May 15, 2015 and is downtrending. It has underperformed by 14.29% the S&P500.
Intersect ENT, Inc. is a commercial-stage drug-device company. The company has a market cap of $558.14 million. The Firm develops drugs for patients with ear, nose and throat conditions. It currently has negative earnings. The Company’s commercial products are the PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis.
According to Zacks Investment Research, “Intersect ENT, Inc. is a commercial drug-device company. The Company’s initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California.”